Contributions
Abstract: PB2319
Type: Publication Only
Background
Myeloid myelofibrosis is a malignant hematologic disease characterized by clonal transformation of the stem cell precursors resulting in medullary myelofibrosis and extramedullary hematopoiesis. Ruxolitinib is a current therapeutic option for patients presenting with splenomegaly and constitutional symptoms.
Aims
The objectives of our work is to analize the results of ruxolitinib treated MF patients in Fundeni Clinical Institute.
Methods
Between January 2014 and December 2017 in our institution, 39 patients diagnosed with primary or secondary myelofibrosis were treated with ruxolitinib. Patients were stratified into risk groups according to the dynamic international prognostic scoring system. We analized the patient data regarding the dose of ruxolitinib, required support treatment including transfusions, required concomitant medication, treatment tolerance, side effects and causes of death. The response evaluation was done by assessing the evolution of constitutional symptoms and splenomegaly.
Results
From 39 MF patients treated with ruxolitinib, 37 were considered evaluable. Median follow-up period was 17 months (3-34 months). 27 (72,97%) patients are still on treatment. There were 10 (27,02%) cases of treatment stop due to: death in 6 (16,21%) patients and treatment failure in 4 (10.81%) patients. The main benefit from ruxolitinib treatment was, as our results showed, the improvement of constitutional symptoms in 31 (83,78%) of the patients. The effects on splenomegaly were similar to those described in the literature. 27 (72,92%) of the patients had a reduction of the spleen size more than 30% at one time in the follow-up period. The toxicities were especially hematologic and the majority were non-severe (grade 1-2). Dose reduction was necesary most frequently due to thrombocytopenia. There were 6 deaths, 4 of them possibly treatment related: 3 cases of respiratory infection and one case of urosepsis. Two patients had acute leukemia transformation of the disease.
Conclusion
Even there are no studies demonstrating the impact of ruxolitinib treatment on overall survival in myelofibrosis patients, its benefits on reducing splenomegaly and improving the constitutional symptoms make ruxolitinib the best available therapy as a symptomatic treatment.
Session topic: 16. Myeloproliferative neoplasms - Clinical
Keyword(s): Myelofibrosis, Ruxolitinib
Abstract: PB2319
Type: Publication Only
Background
Myeloid myelofibrosis is a malignant hematologic disease characterized by clonal transformation of the stem cell precursors resulting in medullary myelofibrosis and extramedullary hematopoiesis. Ruxolitinib is a current therapeutic option for patients presenting with splenomegaly and constitutional symptoms.
Aims
The objectives of our work is to analize the results of ruxolitinib treated MF patients in Fundeni Clinical Institute.
Methods
Between January 2014 and December 2017 in our institution, 39 patients diagnosed with primary or secondary myelofibrosis were treated with ruxolitinib. Patients were stratified into risk groups according to the dynamic international prognostic scoring system. We analized the patient data regarding the dose of ruxolitinib, required support treatment including transfusions, required concomitant medication, treatment tolerance, side effects and causes of death. The response evaluation was done by assessing the evolution of constitutional symptoms and splenomegaly.
Results
From 39 MF patients treated with ruxolitinib, 37 were considered evaluable. Median follow-up period was 17 months (3-34 months). 27 (72,97%) patients are still on treatment. There were 10 (27,02%) cases of treatment stop due to: death in 6 (16,21%) patients and treatment failure in 4 (10.81%) patients. The main benefit from ruxolitinib treatment was, as our results showed, the improvement of constitutional symptoms in 31 (83,78%) of the patients. The effects on splenomegaly were similar to those described in the literature. 27 (72,92%) of the patients had a reduction of the spleen size more than 30% at one time in the follow-up period. The toxicities were especially hematologic and the majority were non-severe (grade 1-2). Dose reduction was necesary most frequently due to thrombocytopenia. There were 6 deaths, 4 of them possibly treatment related: 3 cases of respiratory infection and one case of urosepsis. Two patients had acute leukemia transformation of the disease.
Conclusion
Even there are no studies demonstrating the impact of ruxolitinib treatment on overall survival in myelofibrosis patients, its benefits on reducing splenomegaly and improving the constitutional symptoms make ruxolitinib the best available therapy as a symptomatic treatment.
Session topic: 16. Myeloproliferative neoplasms - Clinical
Keyword(s): Myelofibrosis, Ruxolitinib